Bristol-myers Squibb

This study tests whether luspatercept works better than epoetin alfa for treating anemia in adults with a certain type of low-risk MDS who have not needed blood transfusions or prior anemia drugs. About 360 participants will receive one of the two drugs, and researchers will trac…

This phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…

This study tests whether starting luspatercept (Reblozyl) at the maximum approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 participants who currently need regular transfusions will re…

This study tests whether adding the experimental drug navlimetostat to standard chemotherapy can help people with a specific type of advanced pancreatic cancer (one with an MTAP gene deletion) live longer or slow tumor growth. About 470 adults who have not had prior treatment for…

This phase 3 trial compares a subcutaneous (under-the-skin) injection of the drug combination nivolumab and relatlimab to the standard intravenous (IV) infusion in people with advanced melanoma that cannot be removed by surgery. The study aims to see if the shot delivers enough d…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior tr…

This phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …

This early-stage study tests a new drug combination (BMS-986489) in about 10 Chinese patients whose small cell lung cancer has returned or stopped responding to treatment. The main goals are to check safety and how the drug moves through the body, while also looking for signs tha…

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This study tests a new drug called BMS-986158, either alone or combined with standard treatments (ruxolitinib or fedratinib), in about 216 people with high-risk myelofibrosis, a type of blood cancer. The goal is to see if the drug is safe and can shrink an enlarged spleen, a comm…

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …

This phase 2 trial is testing whether an oral chemotherapy drug called azacitidine (CC-486) can help prevent acute myeloid leukemia from coming back in Chinese patients who are already in complete remission after initial treatment. About 34 participants will receive either the dr…

This study tests the drug mavacamten in 50 adults in India who have a condition where the heart muscle is too thick and blocks blood flow, causing symptoms like shortness of breath and chest pain. The goal is to see if the drug is safe and works well. Participants will take the d…

This study tests an experimental drug, BMS-986278, in about 1057 adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. Participants receive either the drug or a placebo to see if it can slow lung function decline and is safe. The trial is …

This phase 3 study tests whether deucravacitinib, a daily pill, can reduce joint pain and swelling in people with active psoriatic arthritis who have never used biologic drugs. About 670 participants will receive either the drug or a placebo for 16 weeks, with a long-term extensi…

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants w…

This study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…

This study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in real-life clinics across China. Researchers will track skin clearance and symptom improvement in 153 people who are just starting the medication. The goal is to see if results…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…

This phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. About 600 participants will be random…

This phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…

This study tests an experimental drug called BMS-986278 in 1255 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The goal is to see if the drug can slow the decline in lung function and is safe to take. Participants will receive ei…

This study looks at how well and how safely oral azacitidine (ONUREG) works as maintenance therapy for Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants cannot or choose not to have a stem cell transplant. Resear…

This large Phase 3 study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding nivolumab to standard chemotherapy helps people with advanced bladder cancer live longer than chemotherapy alone. About 1,300 participants with untreated, inoperable or m…

This study tests an oral medication called azacitidine (ONUREG) for people with a low- or intermediate-risk form of myelodysplastic syndrome (MDS), a bone marrow disorder. About 230 participants will receive either the drug or a placebo, along with standard supportive care. The g…

This study tests whether taking an oral chemotherapy drug (azacitidine) as maintenance therapy can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older who are already in remission. Participants will receive either the drug or a placebo, al…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than one drug alone (nivolumab) for people with advanced kidney cancer that has not been treated before. About 437 participants with intermediate- or poor-risk disease are in…

This study tests a drug called mavacamten in 44 teenagers aged 12 to 18 who have a condition where the heart muscle is too thick and blocks blood flow. The goal is to see if the drug can reduce the blockage and improve symptoms. Participants are randomly assigned to receive eithe…

This study follows 550 adults with moderate-to-severe plaque psoriasis who are starting deucravacitinib in routine German clinics. Over 5 years, researchers will measure how well the drug clears skin and improves quality of life. The goal is to see how the treatment works outside…

This study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.

This Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…

This phase 3 trial compares two targeted drugs, repotrectinib and crizotinib, in about 190 people with advanced ROS1-positive non-small cell lung cancer who have not had prior targeted therapy. The main goal is to see which drug better delays cancer growth. Participants may have …

This phase 3 trial tests whether the immunotherapy drug nivolumab can prevent liver cancer from coming back in people who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. The…

This study tests a drug called fedratinib in Japanese adults with a serious bone marrow disease called myelofibrosis. The goal is to see if the drug can shrink an enlarged spleen and control the disease. About 31 people will take part, and the study will check safety and the best…

This study follows people with moderate-to-severe plaque psoriasis who have already taken deucravacitinib in earlier trials. It aims to check the drug's long-term safety and how well it controls psoriasis over time. A smaller group will also test how the drug affects immune respo…

This study tests a drug called luspatercept in people with anemia caused by myelodysplastic syndromes (MDS) or beta-thalassemia who need regular blood transfusions. The goal is to see if the drug is safe and can reduce the number of transfusions needed. About 85 participants in I…

This phase 3 trial tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemotherapy before and after surgery can help people with early-stage non-small cell lung cancer live longer without their cancer coming back. About 461 participants will receive either…

This phase 3 trial tests whether the immunotherapy drug nivolumab can delay cancer recurrence in people who have had surgery for high-risk invasive urothelial cancer (a type of bladder cancer). About 709 participants received either nivolumab or a placebo after surgery. The main …

This study tests if a subcutaneous (under-the-skin) injection of the drug nivolumab works as well as the standard intravenous (IV) infusion for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. About 681 participants who have already rec…

This phase 3 trial compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in 839 people with a specific genetic type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if the immunotherapies work better at stopping cancer g…

This phase 4 study tests the drug mavacamten in 63 adults with a type of heart muscle disease called obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve heart structure, measured by MRI, and ease symptoms like shortness of breath. Participants take…

This phase 2 trial tests deucravacitinib, an anti-inflammatory pill, against a placebo in 74 adults with active discoid or subacute cutaneous lupus — skin rashes caused by lupus. The main goal is to see if the drug reduces rash severity after 16 weeks. Participants must already b…

This study tests whether adding a new immunotherapy drug, relatlimab, to the standard drug nivolumab works better than nivolumab alone for people with advanced melanoma that has spread or cannot be removed by surgery. About 714 participants who have not had prior treatment for th…

This study looks at whether people with melanoma prefer getting their cancer medicine as a shot under the skin or through an IV. About 100 patients will try both ways and say which they like better. The goal is to make treatment more convenient and comfortable for patients.

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…

This study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to s…

This study follows 331 adults with hypertrophic cardiomyopathy (HCM) to see how they are treated in everyday medical practice, especially with the drug mavacamten. Researchers will collect data on diagnosis, symptoms, treatments, and outcomes over time. The goal is to understand …

This study looks at health records and insurance claims from nearly 7,000 adults in the U.S. who take KarXT for schizophrenia. Researchers want to understand who gets the drug, how it's used, and how often people need hospital visits. The goal is to see how the medication works i…

This study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…

This study uses a large Spanish database to understand how many people have transfusion-dependent lower-risk myelodysplastic syndromes (MDS) and what treatments they receive first. Researchers will look at medical records of about 1,300 adults to see patterns in care and health o…

This study is observing how well a combination of two immunotherapy drugs (nivolumab and ipilimumab) works for people with advanced non-small cell lung cancer in Italy. Researchers are collecting data from 404 patients to understand real-world outcomes, side effects, and treatmen…

This study was designed to measure how much of the drug ozanimod passes into breast milk and to check for any effects on breastfed infants. It planned to include lactating women already taking ozanimod for medical reasons. However, the study was withdrawn before enrolling any par…

This study is observing over 2,500 people with multiple myeloma to see how well approved treatments work in real-world settings, not just in controlled trials. It includes both newly diagnosed patients and those whose cancer has come back or stopped responding to treatment. The g…

This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…

This study tracks 300 patients with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 1%). Researchers will look at side effects and healthcare use for different first-line treatments, including combinations of immunotherapy drugs like nivolumab and ip…

This study follows 800 children with juvenile idiopathic arthritis who are taking or have taken abatacept. Researchers track serious infections, autoimmune problems, and cancer risks over the long term to better understand the drug's safety. No new treatments are tested—this is a…